The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
As with wide‐spread use of prostate cancer (Pca) screening with prostate‐specific antigen testing, overdetection has increasingly gained attention. The authors aimed to estimate absolute risk of overdetection (RO) in Pca screening with various interscreening intervals and ages at start of screening. We estimated age‐specific preclinical incidence rates (per 100,000 person‐years) for progressive cancer...
To compare the survival between screen‐detected and clinically detected cancers, we applied a series of non‐homogeneous stochastic processes to deal with leadtime, length bias, and over‐detection by using full information on detection modes obtained from the Finnish randomized controlled trial for prostate cancer screening. The results show after 9‐year follow‐up the hazard ratio of prostate cancer...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.